MS4A1 and B-cell non-Hodgkin lymphoma: A noteworthy prospective single-center phase I study, ChiCTR2000036350, demonstrated high efficacy and moderate toxicity of CAR-T cells targeting the CD20 receptor in patients with r/r B-cell NHL treated with rituximab.